Roche Doubles Down on Molecular Glues with Over $2 Billion Orionis Collaboration

—The application for various awards has started successively, stay tuned—

5Month21Day,Orionis BiosciencesAnnounced a second multi-year collaboration with Genentech, a member of the Roche Group, to develop small molecule monovalent molecular glue drugs targeting novel and challenging targets in the field of oncology.

The first collaboration between the two parties was established in2023Year9Month, mainly developing molecular glue drugs targeting challenging targets in disease areas such as cancer and neurodegenerative diseases. The upfront payment for the first collaboration is4700Million USD, Milestone Payment Exceeded20Billion US dollars.

Based on the terms of the latest cooperation agreement,OrionisOrionis Biosciences will be responsible for the discovery and optimization of molecular glues, while Genentech will be responsible for the subsequent preclinical and clinical development, regulatory applications, and commercialization of these molecular glues.OrionisWill Obtain1.05Hundreds of millions of dollars in upfront payments and is eligible to receive potential research, development, commercial, and net sales milestone payments, the total amount of which may exceed20In billions of dollars, as well as potential tiered royalties from collaborative product sales.

OrionisSmall moleculesAllo-Glue™ Platform integrates various proprietary technologies to advance the discovery and design of molecular glues targeting highly challenging disease targets. It combines advanced chemical biology tools, engineered cell analysis systems, customized high-throughput robotic automation, and specialized artificial intelligence (AI) infrastructure, capable of generating and analyzing hundreds of millions of intracellular protein interaction events. These capabilities will accelerate the discovery of monovalent molecular glues and optimize their potency, selectivity, and synthetic accessibility.

“Molecular glue, including protein degraders and non-degraders, is an excitingmodality, providing a new approach to targeting disease-related proteins that have traditionally been challenging. In conjunction withOrionis"The new collaboration is expected to bring revolutionary cancer drugs to patients." Head of Roche Business DevelopmentBoris L. ZaïtraSaid.

In addition toOrionisIn addition to cooperation, Roche is also in2023Year10Month and Molecular Glue Star CompanyMonte Rosa TherapeuticsA strategic partnership was reached, leveraging the latter'sQuEEN™ platform, jointly developing molecular glue degraders targeting undruggable targets in cancer and neurological disorders.Monte RosaWill Obtain5000Million USD upfront payment, milestone payments may also exceed20Billion US dollars.

It is worth mentioning that, except for Roche,OrionisIs also collaborating with Novartis on the development of molecular glue projects.

2024Since the year, the molecular glue field has seen a flurry of transactions, following Novo Nordisk, Takeda, Eisai, Pfizer, and Novartis last year,BiogenAfter stepping up efforts in the molecular glue track,2025YearAbbVie、Eli Lilly and Companyhave also taken action. Combined with Roche's increased investment this time, it increasingly confirms a viewpoint held by industry experts: molecular glue has become an indispensable drug research and development direction for major pharmaceutical companies.

Recommended Reading:

• Cang Yong: "New Thoughts" Amid the Molecular Glue Craze

  
  

References:

[1]https://orionisbio.com/2025/05/genentech-collaboration-2025/

[2]https://www.businesswire.com/news/home/20230920777229/en/Orionis-Biosciences-Announces-Collaboration-with-Genentech-to-Discover-and-Develop-Molecular-Glue-Class-Medicines

[3]https://www.fiercebiotech.com/biotech/roches-genentech-sticks-second-molecular-glue-deal-orionis-worth-2b

PharmaCube Pro

Insights into Global Biomedical Frontiers

Empowering the Transformation of China's Indigenous Innovation Achievements

Media cooperation: 15895423126